Fujifilm Diosynth Biotechnologies opens new laboratory facility in Research Triangle Park, NC
Construction now complete on new 62,000 square foot facility.
Fujifilm Diosynth Biotechnologies has completed the construction of a new three-story, 62,000 square foot state-of-the-art facility in Research Triangle Park, North Carolina. A ribbon cutting ceremony was held on 9 May 2016. Members of the local government and biotech community were in attendance at the event.
“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies.
The new building, called BioProcess Innovation Center, houses the company’s Process and Analytical Research and Development, Process Sciences and Stability groups. These will concentrate on delivering excellence in process invention, design and development and process and product characterization for the company's clients. They will also continue to innovate to further develop systems and approaches which rapidly lead to efficient, robust and high quality biomanufacturing processes.
“The design of the facility reflects our core philosophy of cross-functional collaboration to Research and Process Development which is a key differentiator of our company,” said Martin Meeson, President, Fujifilm Diosynth Biotechnologies USA, Inc. “Developer Alexandria Real Estate Equities, Inc., and General Contractor, KBR Building Group, LLC, brought a wealth of experience in life science building projects to this new addition to Fujifilm Diosynth Biotechnologies, located at 6051 George Watts Hill Drive.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...